Publication: Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10
Issued Date
2014-01-01
Resource Type
ISSN
14321955
09320113
09320113
Other identifier(s)
2-s2.0-84903781590
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Parasitology Research. Vol.113, No.7 (2014), 2559-2568
Suggested Citation
Yang Cheng, Bo Wang, Jetsumon Sattabongkot, Chae Seung Lim, Takafumi Tsuboi, Eun Taek Han Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10. Parasitology Research. Vol.113, No.7 (2014), 2559-2568. doi:10.1007/s00436-014-3907-8 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/33152
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Immunogenicity and antigenicity of Plasmodium vivax merozoite surface protein 10
Other Contributor(s)
Abstract
Among the proteins involved in the invasion by merozoite, the glycosylphosphatidylinositol-anchored proteins (GPI-APs) are suggested as potential vaccine candidates because of their localization to apical organelles and the surface; these candidates are predicted to play essential roles during invasion. As a GPI-AP, Plasmodium vivax merozoite surface protein 10 (PvMSP-10) induces high antibody titers. However, such high antibody titers have shown no protective efficacy for animals challenged with P. vivax parasites in a previous study. To adequately evaluate the immunogenicity and further characterize PvMSP-10 in order to understand its vaccine potential, we assessed its immunogenicity by immunizing BALB/c mice with cell-free expressed recombinant PvMSP-10 protein. The antigenicity of MSP-10 was analyzed, and we found 42 % sensitivity and 95 % specificity using serum samples from P. vivax-infected Korean patients. The IgG1 and IgG3 were the predominant immunoreactive antibodies against PvMSP-10 in vivax patient sera, and IgG1 and IgG3 and Th1-type cytokines were predominantly secreted in PvMSP-10-immunized mice. We conclude that the immunogenicity and antigenicity of MSP-10 may serve as a potential vaccine against vivax malaria. © 2014 Springer-Verlag.